NSE filing, NSE: AEQUS. Summary written from the filing by ALFA Finder's alert engine.
Aequs Ltd: key numbers
- Share price
- ₹211.95
- Market cap
- ₹14,215 Cr
- Revenue (annual)
- ₹1,230 Cr
- Net profit (annual)
- ₹-113.2 Cr
- P/E (TTM)
- -70.4×Sector 52.2×
- Promoter holding
- 59.09%+0.00% QoQ
- FII holding
- 5.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aequs Ltd
All →Aequs Other Announcement
Aequs filed CARE Ratings' quarterly monitoring report on its IPO proceeds for the quarter ended September 2026. The report found no deviation from the stated objects.
Aequs Earnings Call Transcript: Key Takeaways
Aerospace's strong 44% growth is being overshadowed by execution delays and inventory write-downs in the consumer business.
- Call
- Guides 400% growth
Aequs Employee Stock Options
Aequs Limited's NRC granted 2,00,000 employee stock options under its ESOP 2025 plan at an exercise price of ₹235.50. The grant is an employee incentive step, with no cash raised by the company.
- Execution
- Options vest over a minimum of 1 year and are exercisable within 3 years of vesting
Aequs Results Update
Aequs Q2 FY27 revenue rose 45% YoY, but EBITDA fell 45% and losses widened. Consumer ramp slowed, while ₹6,500 Mn promoter warrants fund expansion.
Aequs Investor Presentation: Key Takeaways
H1 FY27 revenue ₹8,046 Mn (+50% YoY); EBITDA ₹460 Mn (6% margin); PAT loss ₹(1,054) Mn as Consumer ramp costs hit.
Aequs Q2 FY27 Results: Net Loss of ₹52.4 Cr, Loss Widens
Aequs Ltd reported revenue from operations of ₹409.1 Cr (+45.3% YoY) and a net loss of ₹52.4 Cr for Q2 FY27.
- Key figure
- Net loss ₹52.4 Cr
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.